ES2679291T3 - Casete de expresión - Google Patents
Casete de expresión Download PDFInfo
- Publication number
- ES2679291T3 ES2679291T3 ES12816132.0T ES12816132T ES2679291T3 ES 2679291 T3 ES2679291 T3 ES 2679291T3 ES 12816132 T ES12816132 T ES 12816132T ES 2679291 T3 ES2679291 T3 ES 2679291T3
- Authority
- ES
- Spain
- Prior art keywords
- gapdh
- promoter
- genomic dna
- dna sequence
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 224
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims abstract description 393
- 239000002773 nucleotide Substances 0.000 claims abstract description 260
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 260
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 246
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 173
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 85
- 229920001184 polypeptide Polymers 0.000 claims abstract description 83
- 238000013518 transcription Methods 0.000 claims abstract description 72
- 230000035897 transcription Effects 0.000 claims abstract description 72
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 56
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 56
- 239000002157 polynucleotide Substances 0.000 claims abstract description 56
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 55
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims abstract description 6
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 382
- 239000012634 fragment Substances 0.000 claims description 186
- 239000013598 vector Substances 0.000 claims description 122
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 239000013604 expression vector Substances 0.000 claims description 67
- 241000699802 Cricetulus griseus Species 0.000 claims description 52
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 101100006921 Homo sapiens NCAPD2 gene Proteins 0.000 claims description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 33
- 230000008488 polyadenylation Effects 0.000 claims description 28
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 19
- 102000004877 Insulin Human genes 0.000 claims description 19
- 108090001061 Insulin Proteins 0.000 claims description 19
- 239000003623 enhancer Substances 0.000 claims description 19
- 229940125396 insulin Drugs 0.000 claims description 19
- 102000047486 human GAPDH Human genes 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 8
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 7
- 241000283984 Rodentia Species 0.000 claims description 6
- 101000710846 Homo sapiens Condensin complex subunit 1 Proteins 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 102100033843 Condensin complex subunit 1 Human genes 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 108700024394 Exon Proteins 0.000 claims 3
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 abstract description 5
- 239000010452 phosphate Substances 0.000 abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 4
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 abstract description 2
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 abstract 10
- 210000004027 cell Anatomy 0.000 description 160
- 108020004414 DNA Proteins 0.000 description 71
- 239000013612 plasmid Substances 0.000 description 49
- 238000001890 transfection Methods 0.000 description 41
- 210000000349 chromosome Anatomy 0.000 description 34
- 238000010367 cloning Methods 0.000 description 32
- 101150112014 Gapdh gene Proteins 0.000 description 31
- 241000700159 Rattus Species 0.000 description 24
- 239000005090 green fluorescent protein Substances 0.000 description 24
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108020004705 Codon Proteins 0.000 description 22
- 230000029087 digestion Effects 0.000 description 22
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 17
- 239000002609 medium Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000010076 replication Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 229960000723 ampicillin Drugs 0.000 description 15
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 229950010131 puromycin Drugs 0.000 description 11
- 230000010474 transient expression Effects 0.000 description 11
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 238000003146 transient transfection Methods 0.000 description 10
- 101000881131 Homo sapiens RNA/RNP complex-1-interacting phosphatase Proteins 0.000 description 9
- 102100037566 RNA/RNP complex-1-interacting phosphatase Human genes 0.000 description 9
- 239000013599 cloning vector Substances 0.000 description 9
- 101100072286 Homo sapiens IFFO1 gene Proteins 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 108091029430 CpG site Proteins 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 238000003153 stable transfection Methods 0.000 description 7
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 230000001174 ascending effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000009331 sowing Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 4
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 4
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 3
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 101100228946 Streptomyces fradiae neoB gene Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102200108237 rs587777558 Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101710137787 Glyceraldehyde-3-phosphate dehydrogenase A Proteins 0.000 description 2
- 101001010832 Homo sapiens Non-homologous end joining factor IFFO1 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101800001646 Protein n Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101100063933 Streptomyces fradiae neoA gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- -1 adresins Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 102000005396 glutamine synthetase Human genes 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241001244729 Apalis Species 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101000580317 Homo sapiens RNA 3'-terminal phosphate cyclase-like protein Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100006922 Mus musculus Ncapd2 gene Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 102100029980 Non-homologous end joining factor IFFO1 Human genes 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102100027566 RNA 3'-terminal phosphate cyclase-like protein Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 244000000009 viral human pathogen Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161567675P | 2011-12-07 | 2011-12-07 | |
| US201161567675P | 2011-12-07 | ||
| PCT/IB2012/056977 WO2013084157A1 (en) | 2011-12-07 | 2012-12-05 | Expression cassette |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2679291T3 true ES2679291T3 (es) | 2018-08-23 |
Family
ID=47561694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12816132.0T Active ES2679291T3 (es) | 2011-12-07 | 2012-12-05 | Casete de expresión |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20130344604A1 (enExample) |
| EP (1) | EP2788483B1 (enExample) |
| JP (3) | JP2015501642A (enExample) |
| KR (1) | KR102135745B1 (enExample) |
| CN (1) | CN104093834A (enExample) |
| AU (2) | AU2012348558A1 (enExample) |
| BR (1) | BR112014013597A2 (enExample) |
| CA (1) | CA2856479A1 (enExample) |
| EA (1) | EA037273B1 (enExample) |
| ES (1) | ES2679291T3 (enExample) |
| HK (1) | HK1202578A1 (enExample) |
| IL (1) | IL232845A0 (enExample) |
| MX (1) | MX362393B (enExample) |
| SG (1) | SG11201402477VA (enExample) |
| WO (1) | WO2013084157A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377591B (es) * | 2014-10-15 | 2025-03-10 | Amgen Inc | Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas. |
| CA2967060A1 (en) * | 2014-11-10 | 2016-05-19 | Murdoch Childrens Research Institute | Vectors and methods for targeted integration in loci comprising constitutively expressed genes |
| CN106868044A (zh) * | 2017-02-15 | 2017-06-20 | 扬州大学 | 一种转基因动物毛色报告基因表达盒、表达载体及应用 |
| JP7520719B2 (ja) * | 2018-03-21 | 2024-07-23 | アルデブロン，エル．エル．シー． | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
| CN114540352A (zh) * | 2022-02-16 | 2022-05-27 | 艾瑞生命科学技术(常州)有限公司 | 一种多核苷酸、载体元件及表达载体和宿主细胞及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) * | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| KR20000006334A (ko) * | 1998-06-26 | 2000-01-25 | 이선경 | 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터 |
| US20040005639A1 (en) * | 2000-08-10 | 2004-01-08 | Ryoichi Ishitani | Glycerylaldehyde-3-phosphate dehyrogenase promoter inducing cell death |
| ATE497009T1 (de) * | 2005-12-12 | 2011-02-15 | King Faisal Specialist Hospital And Res Ct | 3-nichttranslatierte hybridbereiche mit eignung zur effizienten proteinexpression in säugerzellen |
-
2012
- 2012-12-05 HK HK15102932.0A patent/HK1202578A1/xx unknown
- 2012-12-05 CA CA2856479A patent/CA2856479A1/en not_active Abandoned
- 2012-12-05 SG SG11201402477VA patent/SG11201402477VA/en unknown
- 2012-12-05 BR BR112014013597-5A patent/BR112014013597A2/pt not_active Application Discontinuation
- 2012-12-05 EP EP12816132.0A patent/EP2788483B1/en active Active
- 2012-12-05 CN CN201280069001.0A patent/CN104093834A/zh active Pending
- 2012-12-05 US US14/003,410 patent/US20130344604A1/en not_active Abandoned
- 2012-12-05 AU AU2012348558A patent/AU2012348558A1/en not_active Abandoned
- 2012-12-05 JP JP2014545423A patent/JP2015501642A/ja active Pending
- 2012-12-05 KR KR1020147018672A patent/KR102135745B1/ko active Active
- 2012-12-05 ES ES12816132.0T patent/ES2679291T3/es active Active
- 2012-12-05 WO PCT/IB2012/056977 patent/WO2013084157A1/en not_active Ceased
- 2012-12-05 EA EA201491034A patent/EA037273B1/ru unknown
- 2012-12-05 MX MX2014006869A patent/MX362393B/es active IP Right Grant
-
2014
- 2014-05-28 IL IL232845A patent/IL232845A0/en unknown
-
2017
- 2017-05-08 JP JP2017092184A patent/JP2017200476A/ja active Pending
- 2017-07-18 US US15/653,243 patent/US20180163225A1/en not_active Abandoned
-
2018
- 2018-06-18 AU AU2018204332A patent/AU2018204332B2/en active Active
-
2019
- 2019-04-29 US US16/397,006 patent/US20200087679A1/en not_active Abandoned
- 2019-07-04 JP JP2019124927A patent/JP7096790B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015501642A (ja) | 2015-01-19 |
| EP2788483B1 (en) | 2018-06-27 |
| MX2014006869A (es) | 2014-07-14 |
| EP2788483A1 (en) | 2014-10-15 |
| AU2018204332A1 (en) | 2018-07-05 |
| AU2012348558A1 (en) | 2014-07-10 |
| MX362393B (es) | 2019-01-15 |
| JP7096790B2 (ja) | 2022-07-06 |
| SG11201402477VA (en) | 2014-09-26 |
| WO2013084157A1 (en) | 2013-06-13 |
| IL232845A0 (en) | 2014-07-31 |
| JP2019193659A (ja) | 2019-11-07 |
| US20130344604A1 (en) | 2013-12-26 |
| KR20140113666A (ko) | 2014-09-24 |
| US20200087679A1 (en) | 2020-03-19 |
| EA037273B1 (ru) | 2021-03-02 |
| NZ626252A (en) | 2016-06-24 |
| AU2012348558A2 (en) | 2014-07-24 |
| BR112014013597A2 (pt) | 2020-08-18 |
| EA201491034A1 (ru) | 2015-04-30 |
| KR102135745B1 (ko) | 2020-07-21 |
| JP2017200476A (ja) | 2017-11-09 |
| CA2856479A1 (en) | 2013-06-13 |
| HK1202578A1 (en) | 2015-10-02 |
| CN104093834A (zh) | 2014-10-08 |
| AU2018204332B2 (en) | 2020-09-10 |
| US20180163225A1 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2784926T3 (es) | Vector de expresión de mamífero | |
| ES2679291T3 (es) | Casete de expresión | |
| ES2421152T3 (es) | Nuevos elementos reguladores | |
| ES2694778T3 (es) | Vectores de expresión que comprenden secuencias promotoras y potenciadoras quiméricas de citomegalovirus | |
| TW200815591A (en) | Regulatory nucleic acid elements | |
| ES2373549T3 (es) | Método para mejorar la producción de proteínas. | |
| ES3027485T3 (en) | Mammalian cell lines with sirt-1 gene knockout | |
| AU2004295590B2 (en) | Expression systems using mammalian beta-actin promoter | |
| ES2699718T3 (es) | Células para expresión transitoria y usos de las mismas | |
| ES2719108T3 (es) | Vectores y células hospedadoras que comprenden un promotor de SV40 modificado para la expresión de proteínas | |
| JP5554907B2 (ja) | 促進された遺伝子発現能力を伴う新規発現ベクターおよびそれを使用するための方法 | |
| ES2461591T3 (es) | Expresión de proteínas en células de roedor | |
| NZ626252B2 (en) | Expression cassette | |
| WO2025128343A1 (en) | Protein expression using trans-splicing and split selectable markers | |
| ES2821940T3 (es) | Procedimiento para la producción de polipéptidos | |
| HK40061338A (en) | Mammalian cell lines with sirt-1 gene knockout | |
| KR101389088B1 (ko) | 염기서열 최적화된 나트륨-요오드 수송체 유전자 및 그 용도 | |
| JP2010517558A (ja) | オストレオコッカス（Ｏｓｔｒｅｏｃｏｃｃｕｓ）種の核ゲノムからのポリペプチドの発現 | |
| HK1155772B (en) | Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof |